drugset / Trial / NCT01110746

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

NCT01110746

Phase 3 Completed 20 enrolled Biodel
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.

Timeline

Start
2010-02
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous
Subject Viaject 7 Unknown Subcutaneous